Cell microarray technology is a powerful tool for the discovery of human cell surface and secretory protein targets for various antibodies, proteins, and small molecules. This method can process thousands of units simultaneously. By doing so, a global map of cellular functions can be generated.
Creative Biolabs’s unique and highly sensitive Surfarray™ cell microarray technology allows us to provide fast, accurate and efficient solutions to our customers around the world:
Cell-based microarrays can be used in different applications. Our case studies focus on providing more details on receptor identification, targeted deconvolution, and specific screening of biotherapeutics such as CAR T cells and antibodies.
Cellular microarray technology is well suited for target deconvolution. It ranges from the primary targets of revealing antibodies or small molecule compounds identified by phenotypic screening to commercially available drugs. Our microarray technology is widely used for CAR-T and antibody target deconvolution:
Our cell microarrays are optimized for the identification of physiologically relevant cell surface interactions. It recognizes cell surface receptors and secreted targets of a wide range of molecules ranging from purified proteins to more complex ligands such as whole cells:
Identifying new immune checkpoint therapeutic targets provides important business value to our customers. Since many important immune checkpoint interactions have not been fully characterized, we use cell microarray technology to identify immunological checkpoint targets with high specificity.
Contact us to learn about case studies and we'll show you how to use cell microarray technology to identify immune checkpoint targets with high specificity.
Our off-target analysis is used to assess off-targets of plasma membranes and secreted proteins expressed in human cells. Highlights:
Our cell microarray technology can label and screen entire CAR T cells and is widely used to evaluate final engineered cells as well as precursor antibodies/scFv. There are two methods for targeted screening of CAR T cells:
Early specific screening helps to select the right scFv to maximize the chances of producing the most promising potential CAR T therapy. A more relevant assessment of off-target responsibility can then be provided by screening the entire engineered T cell (or final scFv).
Creative Biolabs is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes.
For more detailed information, please feel free to contact us or directly send us an inquiry.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE